@KinatSofrim

Rabbenu Pehter - Seforim advice. NFA.

[@KinatSofrim @kinatsofrim]

For those who've asked in the DMs - Yes, 99% posted is bought (feel free to ask for pgs./opinions about spec. seforim & will try to accommodate). Strictly personal recommendations, hopes to show richness and depths of Torah & to bring to the fore lesser-known authors/titles.

[@KinatSofrim @kinatsofrim]

@endimem_music and Ohad still looks twenty without doing the whole Bryan Johnson regimen

[@KinatSofrim @kinatsofrim]

@endimem_music @DngrousTaxpayer https://t.co/7nnpywP7Ik

[@KinatSofrim @kinatsofrim]

@endimem_music @DngrousTaxpayer Yishai Lapisot

[@KinatSofrim @kinatsofrim]

@MartinShkreli @joshephraim hook Martin up

[@KinatSofrim @kinatsofrim]

@avidresearch @MirzaCPH $RHHBY's atezolizumab showed pMMR HR 0.92 @ 78% maturity - the most mature IO dataset in EC -essentially zero benefit in the exact pop. EC-042 targets, all while their FM is the CDx platform identifying every TP53wt pt who will receive $KPTI's selinexor.

https://t.co/b5uGGThpQt

[@KinatSofrim @kinatsofrim]

@harrisoncn1 @peter_mpn @KartosThera @buysidebio @Biopharmaddict @bose_prithviraj @Blood_Cancers @RaajitRampal @ByMadeleineA @LongwoodLeaders @mpnadvocacy @HealthTree @mpdrc @IcahnMountSinai @pankitvachhani @OncLive @MPN_BMTDOC @sk_tantravahi @AshKishtagari @Yi_Chai18 @CNBCFastMoney @MelissaLeeCNBC @UofUHematology @PeterKolchinsky @MPN_RF @AaronGerds @SGO_org @AACR @CIUSSS_COMTL @MDmasarova @KuykendallMd @WinshipAtEmory $RHHBY has a front row seat to $KPTI's XPORT-EC-042 via subsidiary Foundation Medicine as CDx partner. Dir. Christy Oliger: 20yrs at Genentech/Roche, was on Sierra board when acquired by $GSK for momelotinib & Roche apparently passed on momelotinib.

/408

https://t.co/HUzIYdZrsA

[@KinatSofrim @kinatsofrim]

@avidresearch @MirzaCPH $KPTI Xport-EC-042 PI agreed to Cantor institutional KOL call June 8, 2026 - weeks before EC-042 topline.

https://t.co/93vachXMOl

[@KinatSofrim @kinatsofrim]

$KPTI Thank you Dr. Krivak @AHNtoday "I think SEINDO was I don't want say a sleeper trial... how did this slip by the radar... profound results... absolutely remarkable... tremendously exciting" h/t Dr. Gottfried Konecny @UCLAHealth Dr. Leslie Randall @VCUHealth and @OncLive

[@KinatSofrim @kinatsofrim]

@docusalut @HematoHUSE @SonEspases LMS is predom. TP53wt same biomarker driving $KPTI seli in EC. This P1 confirms 60mg weekly as EC-042 delivering median OS of 39.5 mnths vs 12-18. historically w/ gemcitabine alone, with a 36month OS of 50.2% in one of oncology's most difficult diseases.

https://t.co/CczwD5Xy1Q

[@KinatSofrim @kinatsofrim]

@harrisoncn1 @sk_tantravahi $KPTI Selinexor is a Swiss army knife. 1 drug. 1 mechanism. Multiple indications across TP53wt tumors & XPO1-overexpressing cancers. Works at every Rux dose. Works as monotherapy and across all platelet counts. MF, EC, MM, MDS, AML, NSCLC, TNBC, GBM, ULMS, SGT & counting.

/427

[@KinatSofrim @kinatsofrim]

@endimem_music Big Daf too big to fail and is always shovel ready

[@KinatSofrim @kinatsofrim]

@TannadebeRY https://t.co/T8E1PKFOlN

[@KinatSofrim @kinatsofrim]

@endimem_music did peptides hit Boulevard of the Americas yet?

[@KinatSofrim @kinatsofrim]

@harrisoncn1 @sk_tantravahi $KPTI @DrNeilLove interviews PI and KOL @harrisoncn1 post the ASCO SENTRY presentation:

/430

[@KinatSofrim @kinatsofrim]

$KPTI MF timeline. P1 update at ASH Dec. 2022, then April 2023 at AACR, initiates P3 June 2023, receive FT July 2023 (received OD in Oct. 2022), Nov. 2023 CEO @ Jefferies "Very open to the possibilities to make sure that we maximize the potential of Selinexor + Rux $INCY".

/1

[Juan P. Serrate, DVM @JPZaragoza1]

From Cantor: biotech M&A transactions took an avg of 12.9 mos in 2023. From start of deals talks to deal announcement. Assume deal talks start after data, confirming this and how long after data.

[@KinatSofrim @kinatsofrim]

@harrisoncn1 @sk_tantravahi $KPTI Important highlights from management at Jefferies this morning:

/429

[@KinatSofrim @kinatsofrim]

@rcoledude $KPTI to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 Dr. Robert Coleman, MD, FACOG, FACS, a globally recognized gynecologist oncologist and Principal Investigator of the Phase 3 XPORT-EC-042 trial.

https://t.co/V0TsG2U9jP

[@KinatSofrim @kinatsofrim]

$KPTI 🥁

https://t.co/CdJ4ied1nm

[@KinatSofrim @kinatsofrim]

$KPTI Patients want the therapy now they are more educated then ever & see the unprecedented/robust data & don't want to be on placebo. @Karyopharm do the right thing for patients and file for AA immediately.

[@KinatSofrim @kinatsofrim]

$KPTI Thank you @rcoledude

https://t.co/Efco1o3yT1

[@KinatSofrim @kinatsofrim]

@endimem_music he was on the dais at Adieri

[@KinatSofrim @kinatsofrim]

@endimem_music Need BarberChops to open a location in Avenue of the States asap

[@KinatSofrim @kinatsofrim]

@avidresearch @PositiveTopline CMO from Q1 call...

[@KinatSofrim @kinatsofrim]

@PositiveTopline @avidresearch Fundamental difference w/ SENTRY driven by selinexor's unique anticlonal mechanism (VAF suppression, blast prevention) that pelabresib and momelotinib etc don't have. Those drugs shrink spleens anti-inflammatorily. Selinexor kills the clone. Diff MOA > different OS relationship.

[@KinatSofrim @kinatsofrim]

@avidresearch @PositiveTopline Agree. AA is for drugs waiting to show clinical benefit "reasonably likely to predict clinical benefit" selinexor already has it. Dr. Mascarenhas said it yesterday: "SVR35 correlates with survival benefit - this is not just important for this story, but important for the field."

[@KinatSofrim @kinatsofrim]

@PositiveTopline @avidresearch FDA is looking for a branch to climb down - SVR35 as validated OS surrogate, instrument bias explaining the TSS miss (Dr. Mascarenhas) & VAF + blast suppression + OS HR 0.43 = disease modification profile no prior MF drug ever showed gives them exactly that branch.